Cerus Corporation
NASDAQ•CERS
CEO: Mr. William M. Greenman
Sector: Healthcare
Industry: Medical - Devices
Listing Date: 1997-01-31
Cerus Corporation operates as a biomedical products company. The company focuses on developing and commercializing the INTERCEPT Blood System to enhance blood safety. Its INTERCEPT Blood System, a proprietary technology for controlling biological replication that is designed to reduce blood-borne pathogens in donated blood components intended for transfusion. The company offers INTERCEPT Blood Systems for platelets and plasma, which is designed to inactivate blood-borne pathogens in platelets and plasma donated for transfusion; INTERCEPT Blood System for red blood cells to inactivate blood-borne pathogens in red blood cells donated for transfusion; and INTERCEPT Blood System for Cryoprecipitation that uses its plasma system to produce pathogen reduced cryoprecipitated fibrinogen complex for the treatment and control of bleeding, including massive hemorrhage associated with fibrinogen deficiency, as well as pathogen reduced plasma, cryoprecipitate reduced. It sells platelet and plasma systems through its direct sales force and distributors in the United States, Europe, the Commonwealth of Independent States, the Middle East, Latin America, and internationally. Cerus Corporation was incorporated in 1991 and is headquartered in Concord, California.
Contact Information
Market Cap
$343.99M
P/E (TTM)
-21.8
26.9
Dividend Yield
--
52W High
$2.96
52W Low
$1.12
52W Range
Rank70Top 99.2%
1.1
F-Score
Modified Piotroski Analysis
Based on 10-year fundamentals
Weak • 1.1 / 9 points
Scoring Range (0-9)
8-9: Excellent Value
6-7: Strong Fundamentals
4-5: Average Quality
0-3: Weak Performance
Data Period: 2016-2025
Financial Dashboard
Q4 2025 Data
Revenue
$57.75M+0.00%
4-Quarter Trend
EPS
-$0.01+0.00%
4-Quarter Trend
FCF
$12.31M+0.00%
4-Quarter Trend
2025 Annual Earnings Highlights
Key Highlights
Total Revenue Increased 16% Total revenue reached $233.80M in 2025, marking a 16% increase driven by strong product sales volume.
Product Sales Volume Growth Product revenue was $206.13M, up 14%, primarily due to increased disposable platelet kit and IFC sales in U.S.
Net Loss Significantly Narrows Net loss attributable to stockholders improved to $15.63M, down from $20.92M loss reported in the prior year.
Government Contract Revenue Jumps Government contract revenue grew 31% to $27.67M, boosted by execution of the new 2024 BARDA Agreement.
Risk Factors
Red Blood Cell Approval Uncertainty Red blood cell system development costs ongoing; certification review transferred to ANSM, timeline unpredictable.
Reliance on Sole Source Suppliers Sole source suppliers for key components like Fresenius expose manufacturing and supply chain continuity to significant risk.
U.S. Market Adoption Critical Business success substantially depends on achieving broad market acceptance and sales execution for INTERCEPT in U.S.
Macroeconomic and Tariff Headwinds Escalating trade tensions, tariffs, and economic uncertainty may increase operating costs and negatively affect gross margins.
Outlook
Red Blood Cell PMA Submission Plan to submit modular PMA application for red blood cell system, including supplemental European clinical data, in late 2026.
IFC Sales Model Transition Shifting focus for IFC from selling finished therapeutic doses to hospitals towards selling kits to blood centers.
New Illuminator PMA Planned Plan to submit PMA application for new LED-based illuminator for platelet and plasma systems in mid-2026.
Capital Needs Dependent Funding Future growth and development depend on continued access to government contract funding and public/private equity markets.
Peer Comparison
Revenue (TTM)
$349.88M
$329.52M
$206.13M
Gross Margin (Latest Quarter)
684.5%
87.3%
86.3%
Key Metrics
Symbol | Market Cap | P/E (TTM) | ROE (TTM) | Debt to Assets |
|---|---|---|---|---|
| TCMD | $625.15M | 32.7 | 9.3% | 5.8% |
| NPCE | $491.87M | -22.3 | -105.7% | 67.1% |
| CERS | $343.99M | -21.8 | -26.4% | 43.7% |
Long-Term Trends
Last 4 Quarters
Revenue
Net Income
Operating Cash Flow
4Q Revenue CAGR
10.1%
Steady Growth
4Q Net Income CAGR
N/M
Profitability Shift
Cash Flow Stability
50%
Cash Flow Needs Attention
Deep Research
Next earnings:Apr 29, 2026
EPS:-
|Revenue:-
Financials
Earnings Calls
Reports
News
Income Statement
Balance Sheet
Cash Flow Statement
Ratios
% Chg.
Income Statement | LTM |
|---|
No Data